Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Certain Factors May Predict Lung Cancer Patients’ Response to Chemotherapy

In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis.

Wednesday, January 10, 2018 12:01 am EST
"Patients’ clinical pathological characteristics may be used to predict the therapeutic efficacy of chemotherapy and survival"

In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis.

 “Patients’ clinical pathological characteristics may be used to predict the therapeutic efficacy of chemotherapy and survival,” the authors wrote.


Additional Information

Link to Study: http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12581/full

About Journal

Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society.

Multimedia Files:

Preview image

Contact:

Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com

Business Wire NewsHQsm